Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 425-433

  Ayaori, Makoto ^a   Momiyama, Yukihiko ^b   Fayad, Zahi A ^d   Yonemura, Atsushi ^a   Ohmori, Reiko ^a   Kihara, Teruyoshi ^c   Tanaka, Nobukiyo ^a   Nakaya, Kazuhiro ^a   Ogura, Masatsune ^a   Sawada, Shojiro ^a   Taniguchi, Hiroaki ^a   Kusuhara, Masatoshi ^a   Nagata, Masayoshi ^c   Nakamura, Haruo ^a   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^c Iruma Heart Hospital   (Japan)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerotic plaque; Fibrates; HDL cholesterol; MRI; Triglycerides

Indexed keywords

BEZAFIBRATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; IMAGING; KIDNEY DYSFUNCTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AGED; ANTILIPEMIC AGENTS; AORTA; ATHEROSCLEROSIS; BEZAFIBRATE; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 38049086651     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.11.035     Document Type: Article

References (28)

1. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
2. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 10 (2004) 2678-2686
3. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317 (1987) 1237-1245
4. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
5. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
6. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102 (2000) 21-27
7. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366 (2005) 1849-1861
8. Vallilainen J., Steiner G., Ansquer J.C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
9. Fayad Z.A., Nahar T., Fallon J.T., et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101 (2000) 2503-2509
10. Taniguchi H., Momiyama Y., Fayad Z.A., et al. In vivo magnetic resonance evaluation of associations between aortic atherosclerosis and both risk factors and coronary artery disease in patients referred for coronary angiography. Am Heart J 148 (2004) 137-143
11. Worthley S.G., Helft G., Fuster V., et al. High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis 150 (2000) 321-329
12. Helft G., Worthley S.G., Fuster V., et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. J Am Coll Cardiol 37 (2001) 1149-1154
13. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lip id-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-743
14. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
15. Chan S.K., Jaffer A., Botnar R.M., et al. Scan reproducibility of magnetic resonance imaging assessment of aortic atherosclerosis burden. J Cardiovasc Magn Reson 3 (2001) 331-338
16. Shinnar M., Fallon J.T., Wehrli S., et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol 19 (1999) 2756-2761
17. Corti R, Osende J, Hutter R, et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis; in press.
18. Tribouilloy C.M., Peltier M., Lannetta-Peltier M.C., et al. Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. Am J Cardiol 84 (1999) 603-605
19. Giral P., Pithois-Merli I., Filitti V., et al. Prevention cardio-vasculaire en Medecine du Travail METRA Group. Risk factors and early extracoronary atherosclerotic plaques detected by three-site ultrasound imaging in hypercholesterolemic men. Arch Intern Med 151 (1991) 950-956
20. Berenson G.S., Srinivasan S.R., Bao W., et al., for the Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 338 (1998) 1650-1656
21. Reed D.M., Strong J.P., Resch J., and Hayashi T. Serum lipids and lipoproteins as predictors of atherosclerosis: an autopsy study. Arteriosclerosis 9 (1989) 560-564
22. Ruotolo G., Ericsson C.G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
23. Fuster V., Moreno P.R., Fay ad Z.A., Corti R., and Badimon J.J. Atherothrombosis and high-risk plaque. Part I. J Am Coll Cardiol 46 (2005) 937-954
24. Ikewaki K., Noma K., Tohyama J., Kido T., and Mochizuki S. Effects of bezafibrate on lipoprotein subclass and inflammatory markers in patients with hypertriglyceridemia: a nuclear magnetic resonance study. Int J Cardiol 101 (2005) 441-447
25. La Ville A.E., Sola R., Motta C., et al. Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovasc Drugs Ther 11 (1997) 653-658
26. Soedamah-Muthu S.S., Colhoun H.M., Thomason M.J., et al. The CARDS investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischemic heart disease. Atherosclerosis 167 (2003) 243-255
27. Reed D., Reed C., Stemmermann G., and Hayashi T. Are aortic aneurysms caused by atherosclerosis?. Circulation 85 (1992) 205-211
28. Dobrin P., Baker W., and Gley W. Elastolytic and collagenolytic studies of arteries. Arch Surg 119 (1984) 405-409